Versant Ventures related stories
All articles and analysis
An eye for an IPOHealthcare investors, like Versant and others, are looking at plenty of ophthalmic deals and exits
Versant places Mazzo on administrative leave following indictmentVersant Ventures has placed operating partner Jim Mazzo on administrative leave following a federal grand jury indictment for alleged insider trading, a source at Versant confirmed. Both Mazzo and Versant have mutually agreed that Mazzo will suspend his work at the healthcare-focused venture firm until his legal matters are resolved.
- Northleaf Capital holds second close on $233.5 mln for venture fund of funds
Northleaf Capital Partners has held a second closing on its Venture Catalyst Fund, bringing commitments to date to $233.5 million. The fund of funds, the first to be established under the Canadian government's Venture Capital Action Plan, began investing in January and has made six investments, including three fund commitments to Versant Ventures, Georgian Partners and XPV Capital.
Manulife Financial helps NVCF get to $233.5 mln second closeNorthleaf Venture Catalyst Fund (NVCF), the first market-based fund-of-funds backed by Ottawa’s $400 million Venture Capital Action Plan in partnership with the Ontario government, has raised $233.5 million in its second close. The first close, announced /canada/2014/01/21/first-vcap-fund-of-funds-northleaf-venture-catalyst-fund-nets-218-mln-in-initial-close/ in January, brought in $218 million. The NVCF's most recent investor is Canadian insurance company and financial services provider Manulife Financial. NVCF, which is managed by global private markets fund manager Northleaf Capital Partners, invests primarily in Canadian venture capital and growth equity funds and direct co-investment opportunities. To date, it has made six investments.
- IPO Profile: Immune Design Corp
Alta Partners, Column Group, ProQuest, Topspin and Versant Ventures saw a 9.4x return on the IPO
Neuroscience deals a no-brainerThe human brain may be complicated, but more VCs are finding it easy to back drug developers focused on neurological conditions
VCs on the move Jul 1, 2014Canvas adds a fourth partner; Foundation boosts staff; and Venrock adds a biotech investor
- NVCF supports Versant Ventures' Canadian expansion
Northleaf Venture Catalyst Fund has committed $10 million to healthcare-focused Versant Ventures. The capital will be used to support the firm's continued Canadian expansion. Currently, Versant Ventures has incubators in Vancouver, Toronto and Montreal.
Teralys, Fonds de solidarité FTQ, BDC invest in Versant VenturesCanadian technology-focused fund-of-funds manager Teralys Capital has partnered with the Fonds de solidarité des travailleurs du Québec FTQ and BDC Venture Capital in backing U.S. life sciences venture capital firm Versant Ventures. Teralys committed $25 million to Versant, making its fifth investment in life sciences, an integral part of Teralys' and its partners' strategy to bolster the market ecosystem in Québec and across Canada. The three investor groups also plan to work with the firm on its recently launched /canada/2014/06/24/versant-ventures-brings-inception-sciences-to-montreal/ drug discovery incubator Inception Sciences, located in Montréal. Northleaf Venture Catalyst Fund also announced /canada/2014/06/24/nvcf-commits-10-mln-to-canadian-expansion-of-versant-ventures/ a $10 million commitment to Versant.
- Teralys, Fonds de solidarité FTQ, BDC invest in Versant Ventures
Canadian technology-focused fund-of-funds manager Teralys Capital has partnered with the Fonds de solidarité des travailleurs du Québec FTQ and BDC Venture Capital in backing U.S. life sciences venture capital firm Versant Ventures. Teralys committed $25 million to Versant, making its fifth investment in life sciences, an integral part of Teralys' and its partners' strategy to bolster the market ecosystem in Québec and across Canada. The three investor groups also plan to work with the firm on its recently launched /canada/2014/06/24/versant-ventures-brings-inception-sciences-to-montreal/ drug discovery incubator Inception Sciences, located in Montréal. Northleaf Venture Catalyst Fund also announced /canada/2014/06/24/nvcf-commits-10-mln-to-canadian-expansion-of-versant-ventures/ a $10 million commitment to Versant.